Publications by authors named "R Craciun"
The connections between sarcopenia and various chronic conditions, including type 2 diabetes (T2DM), metabolic syndrome (MetS), and liver disease have been highlighted recently. There is also a high occurrence of sarcopenia in metabolic dysfunction-associated steatotic liver disease (MASLD) patients, who are often disregarded. Both experimental and clinical findings suggest a complex, bidirectional relationship between MASLD and sarcopenia.
View Article and Find Full Text PDFThis review addresses the peri-procedural bleeding risks in patients with cirrhosis, emphasizing the need for careful coagulation assessment and targeted correction strategies. Liver disease presents a unique hemostatic challenge, where traditional coagulation tests may not accurately predict bleeding risk, complicating the management of procedures like paracentesis, endoscopic therapy, and various interventional procedures. As such, this paper aims to provide a comprehensive analysis of current data, guidelines, and practices for managing coagulation in cirrhotic patients, with a focus on minimizing bleeding risk while avoiding unnecessary correction with blood products.
View Article and Find Full Text PDF(1) Background: Cirrhosis is associated with frequent alterations in standard coagulation tests that do not adequately reflect hemostasis. Thromboelastography provides a global assessment of coagulation and evaluates the functional status of clotting factors, fibrinogen, platelets, and fibrinolysis. The study aimed to assess whether liver disease severity leads to progressive alterations in the thromboelastography-based assessment of coagulation.
View Article and Find Full Text PDFArticle Synopsis
- Sarcopenia, characterized by muscle mass loss, is found in up to 68% of rectal cancer patients and negatively affects survival and tumor response, although research on its impact in locally advanced rectal cancer (LARC) is limited.
- A study at the Prof. Dr. Ion Chiricuta Institute of Oncology examined 50 LARC patients who underwent total neoadjuvant treatment (TNT), assessing muscle mass via MRI before and after therapy.
- The findings showed that a lower overall complete response rate (oCR) of 18% was significantly tied to post-treatment sarcopenia, and patients who experienced muscle loss during therapy had worse clinical outcomes and higher instances of cystitis and thrombocytopenia.
Article Synopsis
- * Using high-throughput mass spectrometry, the study identified 845 proteins, highlighting significant differences in protein levels among the conditions, with S100A9 and haptoglobin elevated in iCCA and ICAM2 in HCC.
- * Key findings suggest that serum amyloid A proteins (SAA1 and SAA4) as well as VCAM-1 and TEK may serve as potential biomarkers for distinguishing iCCA and HCC, emphasizing the need for further validation of these findings.